Promising therapeutic strategies for Lennox-Gastaut syndrome: what’s new? DOI
Frank Besag, Michael J. Vasey,

Roy Brown

et al.

Expert Review of Neurotherapeutics, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 13

Published: Dec. 21, 2024

Introduction The seizures in Lennox-Gastaut syndrome are typically resistant to treatment. Seven antiseizure medications (ASMs) the US (six UK/EU) licensed for treatment of LGS: lamotrigine, topiramate, rufinamide, clobazam, felbamate (not UK/EU), cannabidiol and fenfluramine. Other options include neurostimulation, corpus callosotomy dietary therapies, principally ketogenic diet its variants. New treatments therapeutic strategies needed improve management both cognitive/behavioral comorbidities LGS.

Language: Английский

Bioelectronic Therapies for Chronic Pain DOI

Liam Matthews,

Scott F. Lempka

Current Opinion in Biomedical Engineering, Journal Year: 2025, Volume and Issue: 34, P. 100577 - 100577

Published: Jan. 20, 2025

Language: Английский

Citations

0
Are we ready for automated deep brain stimulation programming? DOI
Eric R. Cole, Svjetlana Miocinovic

Parkinsonism & Related Disorders, Journal Year: 2025, Volume and Issue: unknown, P. 107347 - 107347

Published: Feb. 1, 2025

Language: Английский

Citations

0
A comprehensive review of neurotransmitter modulation via artificial intelligence: A new frontier in personalized neurobiochemistry DOI

Jaleh Bagheri Hamzyan Olia,

Arasu Raman, Chou‐Yi Hsu

et al.

Computers in Biology and Medicine, Journal Year: 2025, Volume and Issue: 189, P. 109984 - 109984

Published: March 14, 2025

Language: Английский

Citations

0
Peri-Lead Edema in Deep Brain Stimulation: Long-Term Outcomes and Possible Etiological Correlates DOI
Luigi Gianmaria Remore, Giorgio Fiore, Elena Pirola

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: May 5, 2025

Abstract Background Deep brain stimulation (DBS) is an effective surgical procedure for the treatment of Parkinson’s disease (PD) and other movement disorders. Immediate delayed complications after DBS surgery have been described. Peri-lead edema (PLE) a DBS-related complication whose etiology still unknown. Moreover, PLE frequency long-term effects are subjects ongoing debate. Objectives To elucidate clinical neuropsychological to find possible etiological correlates. Methods We retrospectively collected data from 51 PD patients before one year DBS. visualized on FLAIR MRI sequence was manually segmented. Using appropriate statistical tests, continuous categorical variables were compared between with without PLE. A multivariate regression model employed analyze contribution volume changes. Results 68.62% presented at immediate postoperative MRI. Patients significantly older (p<0.001) had more frequent confusion episodes (p=0.025). Furthermore, MER (microelectrode recording) tracks used in Multiple directly correlated only significant predictors changes model. No differences found variables. Conclusions post-surgical event may cause transient confusion. It seems linked age multiple tracks. Although it does not influence global motor outcomes, contributes episodes. avoid sequelae, using should be discouraged.

Language: Английский

Citations

0
Neural circuit mechanisms of epilepsy: Maintenance of homeostasis at the cellular, synaptic, and neurotransmitter levels DOI Creative Commons

Xueqing Du,

Yi Wang, Xuefeng Wang

et al.

Neural Regeneration Research, Journal Year: 2025, Volume and Issue: 21(2), P. 455 - 465

Published: Jan. 13, 2025

Epilepsy, a common neurological disorder, is characterized by recurrent seizures that can lead to cognitive, psychological, and neurobiological consequences. The pathogenesis of epilepsy involves neuronal dysfunction at the molecular, cellular, neural circuit levels. Abnormal molecular signaling pathways or specific cell types disrupting normal functioning circuits. continuous emergence new technologies rapid advancement existing ones have facilitated discovery comprehensive understanding mechanisms underlying epilepsy. Therefore, this review aims investigate current in based on various technologies, including electroencephalography, magnetic resonance imaging, optogenetics, chemogenetics, deep brain stimulation, brain–computer interfaces. Additionally, discusses these from three perspectives: structural, synaptic, transmitter findings reveal encompass information transmission among different structures, interactions within same structure, maintenance homeostasis neurotransmitter These offer insights for investigating pathophysiological enhancing its clinical diagnosis treatment.

Language: Английский

Citations

0
AI-Driven Advances in Parkinson’s Disease Neurosurgery: Enhancing Patient Selection, Trial Efficiency, and Therapeutic Outcomes DOI Creative Commons
José E. Valerio,

Guillermo de Jesús Aguirre Vera,

Maria Paula Fernandez

et al.

Brain Sciences, Journal Year: 2025, Volume and Issue: 15(5), P. 494 - 494

Published: May 9, 2025

Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by motor and non-motor dysfunctions that severely compromise patients’ quality of life. While pharmacological treatments provide symptomatic relief in the early stages, advanced PD often requires neurosurgical interventions, such as deep brain stimulation (DBS) focused ultrasound (FUS), for effective symptom management. A significant challenge optimizing these therapeutic strategies identification recruitment suitable candidates clinical trials. This review explores role artificial intelligence (AI) advancing neuroscience interventions PD, highlighting ways which AI-driven platforms are transforming trial design patient selection. Machine learning (ML) algorithms big data analytics enable precise stratification, risk assessment, outcome prediction, accelerating development novel approaches. These innovations improve efficiency, broaden treatment options, enhance outcomes. However, integrating AI into frameworks presents challenges standardization, regulatory hurdles, need extensive validation. Addressing obstacles will require collaboration among neurosurgeons, neuroscientists, specialists, bodies to establish ethical guidelines technologies research. paper emphasizes transformative potential technological innovation shaping future neurosurgery, ultimately enhancing efficacy care.

Language: Английский

Citations

0
Why are clinical trials of deep brain stimulation terminated? An analysis of clinicaltrials.gov DOI Creative Commons
Akash Mishra, Sabrina L. Begley, Harshal A. Shah

et al.

World Neurosurgery X, Journal Year: 2024, Volume and Issue: 23, P. 100378 - 100378

Published: April 4, 2024

Although deep brain stimulation (DBS) has established uses for patients with movement disorders and epilepsy, it is under consideration a wide range of neurologic neuropsychiatric conditions.

Language: Английский

Citations

3
Navigating Deep Brain Stimulation Targets: A Three-Dimensional Video Guide for Movement Disorders DOI
Umut Tan Sevgi, Gökberk Erol, Yücel Doğruel

et al.

World Neurosurgery, Journal Year: 2024, Volume and Issue: 192, P. 126 - 126

Published: Oct. 9, 2024

Language: Английский

Citations

0
Predictive modeling of sensory responses in deep brain stimulation DOI Creative Commons
László Halász, Bastian Sajonz,

Gabriella Miklós

et al.

Frontiers in Neurology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 1, 2024

Introduction Although stimulation-induced sensations are typically considered undesirable side effects in clinical DBS therapy, there emerging scenarios, such as computer-brain interface applications, where these may be intentionally created. The selection of stimulation parameters, whether to avoid or induce sensations, is a challenging task due the vast parameter space involved. This study aims streamline by employing machine learning model predict occurrence and somatic location paresthesias response thalamic DBS. Methods We used dataset comprising 3,359 paresthetic collected from 18 leads 10 individuals two centers. For each stimulation, we modeled Volume Tissue Activation (VTA). then parameters VTA information train their corresponding areas. Results Our results show fair substantial agreement with ground truth predicting presence DBS-evoked paresthesias, Kappa values ranging 0.31 0.72. observed comparable performance for both seen unseen cases (Kappa 0.72 vs. 0.60). However, specific locations was significantly lower (0.53 0.31). Conclusion suggest that can potentially optimize selection, leading faster more efficient postoperative management. Outcome predictions guide programming tuning based interfaces.

Language: Английский

Citations

0
Promising therapeutic strategies for Lennox-Gastaut syndrome: what’s new? DOI
Frank Besag, Michael J. Vasey,

Roy Brown

et al.

Expert Review of Neurotherapeutics, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 13

Published: Dec. 21, 2024

Introduction The seizures in Lennox-Gastaut syndrome are typically resistant to treatment. Seven antiseizure medications (ASMs) the US (six UK/EU) licensed for treatment of LGS: lamotrigine, topiramate, rufinamide, clobazam, felbamate (not UK/EU), cannabidiol and fenfluramine. Other options include neurostimulation, corpus callosotomy dietary therapies, principally ketogenic diet its variants. New treatments therapeutic strategies needed improve management both cognitive/behavioral comorbidities LGS.

Language: Английский

Citations

0